| # | Title | Journal | Year | Citations |
|---|
| 1 | SARS‐CoV‐2 Omicron variant: Characteristics and prevention | MedComm | 2021 | 364 |
| 2 | NF‐κB signaling in inflammation and cancer | MedComm | 2021 | 107 |
| 3 | Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities | MedComm | 2022 | 102 |
| 4 | Lipid metabolism in cancer progression and therapeutic strategies | MedComm | 2021 | 101 |
| 5 | Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment | MedComm | 2021 | 99 |
| 6 | Metabolism in tumor microenvironment: Implications for cancer immunotherapy | MedComm | 2020 | 93 |
| 7 | The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19 | MedComm | 2022 | 79 |
| 8 | Biodegradable magnesium‐based biomaterials: An overview of challenges and opportunities | MedComm | 2021 | 77 |
| 9 | A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential | MedComm | 2021 | 76 |
| 10 | SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development | MedComm | 2022 | 74 |
| 11 | Mitochondria as a target in cancer treatment | MedComm | 2020 | 57 |
| 12 | Engineered biomaterials for cancer immunotherapy | MedComm | 2020 | 52 |
| 13 | Zeolite in tissue engineering: Opportunities and challenges | MedComm | 2020 | 51 |
| 14 | SARS‐CoV‐2 Omicron variant: A next phase of the COVID‐19 pandemic and a call to arms for system sciences and precision medicine | MedComm | 2022 | 45 |
| 15 | Redox signaling at the crossroads of human health and disease | MedComm | 2022 | 44 |
| 16 | STAT3 pathway in cancers: Past, present, and future | MedComm | 2022 | 43 |
| 17 | Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities | MedComm | 2022 | 43 |
| 18 | Tumor metastasis: Mechanistic insights and therapeutic interventions | MedComm | 2021 | 42 |
| 19 | Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy | MedComm | 2021 | 38 |
| 20 | The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants | MedComm | 2023 | 38 |
| 21 | A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virus | MedComm | 2021 | 37 |
| 22 | The challenges of COVID‐19 Delta variant: Prevention and vaccine development | MedComm | 2021 | 37 |
| 23 | Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras | MedComm | 2021 | 36 |
| 24 | Targeting DNA repair pathway in cancer: Mechanisms and clinical application | MedComm | 2021 | 34 |
| 25 | Graphene and graphene oxide with anticancer applications: Challenges and future perspectives | MedComm | 2022 | 30 |
| 26 | COVID‐19: A systematic review and update on prevention, diagnosis, and treatment | MedComm | 2022 | 30 |
| 27 | Autophagy in health and disease: From molecular mechanisms to therapeutic target | MedComm | 2022 | 30 |
| 28 | The emerging role of neutrophils in autoimmune‐associated disorders: effector, predictor, and therapeutic targets | MedComm | 2021 | 28 |
| 29 | The role of necroptosis in disease and treatment | MedComm | 2021 | 27 |
| 30 | Molecular mechanisms and therapeutic target of NETosis in diseases | MedComm | 2022 | 27 |
| 31 | Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China | MedComm | 2020 | 26 |
| 32 | Nasally inhaled therapeutics and vaccination for COVID‐19: Developments and challenges | MedComm | 2021 | 26 |
| 33 | Small molecule inhibitors targeting the cancers | MedComm | 2022 | 25 |
| 34 | Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma | MedComm | 2021 | 24 |
| 35 | Regulatory T cells: A potential weapon to combat COVID‐19? | MedComm | 2020 | 22 |
| 36 | Coronavirus in human diseases: Mechanisms and advances in clinical treatment | MedComm | 2020 | 22 |
| 37 | Role of chemokine systems in cancer and inflammatory diseases | MedComm | 2022 | 22 |
| 38 | SARS‐CoV‐2 triggered oxidative stress and abnormal energy metabolism in gut microbiota | MedComm | 2022 | 21 |
| 39 | Role of protein phosphorylation in cell signaling, disease, and the intervention therapy | MedComm | 2022 | 21 |
| 40 | The molecular pathophysiology of depression and the new therapeutics | MedComm | 2022 | 20 |
| 41 | Animal models for SARS‐CoV‐2 infection and pathology | MedComm | 2021 | 19 |
| 42 | COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies | MedComm | 2023 | 19 |
| 43 | Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD | MedComm | 2022 | 18 |
| 44 | LncRNAs and CircRNAs in cancer | MedComm | 2022 | 18 |
| 45 | Metabolic reprogramming in cancer: Mechanisms and therapeutics | MedComm | 2023 | 18 |
| 46 | Carbon nanoparticles suspension injection for photothermal therapy of xenografted human thyroid carcinoma in vivo | MedComm | 2020 | 17 |
| 47 | Alleviating the toxicity concerns of antibacterial cinnamon‐polycaprolactone biomaterials for healthcare‐related biomedical applications | MedComm | 2021 | 17 |
| 48 | Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions | MedComm | 2022 | 17 |
| 49 | Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications | MedComm | 2023 | 17 |
| 50 | Nanoparticles‐induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models | MedComm | 2023 | 17 |
